Company intelligence / Profile preview

Imagine Dragons

Pittsburgh, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Imagine Pharma is a biotechnology company focused on the development of a proprietary polypeptide platform, specifically the IMG-1 polypeptide, to address significant unmet medical needs. The company's lead programs target Alpha-1 Antitrypsin Deficiency (AATD) and Type 1 Diabetes, leveraging the unique biological properties of IMG-1 to modulate immune responses and promote tissue regeneration. Beyond metabolic and genetic disorders, Imagine Pharma is exploring applications in inflammatory bowel disease and chronic wound healing. The company aims to translate its foundational polypeptide science into a diverse pipeline of therapeutic candidates.

Therapeutic areas: EndocrinologyDermatologyRare DiseasesGastroenterology
Modalities: PeptidesPolypeptides
Industry: Biotech

Beyond the preview

Go deeper on Imagine Dragons.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imagine Dragons.

Explore the full profile